Legal & General Group Plc grew its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,133,331 shares of the company’s stock after acquiring an additional 129,247 shares during the quarter. AbbVie comprises approximately 0.6% of Legal & General Group Plc’s portfolio, making the stock its 17th biggest holding. Legal & General Group Plc’s holdings in AbbVie were worth $2,772,345,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after acquiring an additional 3,032,438 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Amundi lifted its position in shares of AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of AbbVie by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after acquiring an additional 408,426 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of AbbVie by 2.4% in the third quarter. Raymond James Financial Inc. now owns 9,557,701 shares of the company’s stock valued at $2,212,110,000 after acquiring an additional 220,221 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
AbbVie Stock Performance
NYSE ABBV opened at $216.02 on Monday. AbbVie Inc. has a one year low of $181.71 and a one year high of $244.81. The company’s 50 day moving average price is $208.72 and its 200 day moving average price is $219.73. The firm has a market capitalization of $381.65 billion, a price-to-earnings ratio of 106.41, a PEG ratio of 0.74 and a beta of 0.32.
Insider Transactions at AbbVie
In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on ABBV shares. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research report on Thursday, April 30th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 17th. Finally, Citigroup dropped their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $253.43.
Get Our Latest Stock Analysis on AbbVie
Trending Headlines about AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
- Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
- Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
- Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
- Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More
- Five stocks we like better than AbbVie
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
